La cadena de opciones muestra datos clave de las opciones de acciones de Coherus Oncology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Coherus Oncology..

Coherus Oncology (NASDAQ:CHRS) Bolsa, Cadena de Opciones

COHERUS ONCOLOGY INC

Coherus BioSciences

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Businessman,Using,A,Mobile,Phone,To,Check,Stock,Market,Data,

Equities

Technicals

Markets

Trading Ideas

ALDX

ALEC

BDTX

CHRS

El sector biotecnológico destaca por un repunte de momentum: descubre qué impulsa a estas acciones y cómo interpretar sus percentiles.

4 acciones biotecnológicas con momentum en máximos semanales según su percentil

Coherus Oncology Inc

News

Press Releases

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Coherus to Participate in Upcoming Investor Conferences

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Earnings

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Health Care

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

C4 Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Fate Therapeutics

Foghorn Therapeutics

Genfit

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Seres Therapeutics

Nkarta

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Pyxis Oncology

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Vor Biopharma

Zura Bio Limited - Class A Ordinary shares

Comments

Coherus Oncology

Coherus Oncology (CHRS) Opciones

Coherus Oncology (NASDAQ:CHRS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL